Search

everythinglearnresearchcommunity

for

Search:↓

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Old drugs like finasteride and spironolactone are being successfully used for hair loss and skin conditions, and many other drugs show promise for new uses in dermatology.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

New treatments for chronic central serous chorioretinopathy show promise in preventing permanent vision loss.

Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.

Tailored medication preparation and ongoing education are crucial for effective treatments.

Spironolactone helps reduce fluid in the eye in Central Serous Chorioretinopathy, but doesn't improve vision and recurrence is common.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Promising cancer treatments were found, but the manufacturer closed.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Targeted cancer therapies often cause serious skin problems that need careful management.